Table 4.
Selected ongoing clinical trials inhibiting autophagy in cancer.
| Cancer type | Treatment | Study phase | ClinicalTrials.gov identifier [201] |
|---|---|---|---|
| Glioblastoma multiforme | Hydroxychloroquine, radiation, temozolomide | I/II | NCT00486603 |
| Multiple myeloma | Hydroxychloroquine, bortezomib | I/II | NCT00568880 |
| Advanced non-small-cell lung cancer | Hydroxychloroquine, carboplatin, paclitaxel, bevacizumab | I/II | NCT00728845 |
| Breast (metastatic) | Hydroxychloroquine, ixabepilone | I/II | NCT00765765 |
| Colorectal (metastatic) | Hydroxychloroquine, capecitabine, oxaliplatin, bevacizumab | II | NCT01006369 |
| Prostate | Hydroxychloroquine | II | NCT00726596 |
| Renal cell carcinoma | Hydroxychloroquine, surgery | I | NCT01144169 |
| Breast (DCIS) | Chloroquine, tamoxifen | I/II | NCT01023477 |
| Prostate (metastatic) | Hydroxychloroquine, docetaxel | I/II | NCT00786682 |
| Lung | Hydroxychloroquine, gefitinib | I/II | NCT00809237 |
DCIS: Ductal carcinoma in situ.